Cargando…

Anti-c-myc RNAi-Based Onconanotherapeutics

Overexpression of the c-myc proto-oncogene features prominently in most human cancers. Early studies established that inhibiting the expression of oncogenic c-myc, produced potent anti-cancer effects. This gave rise to the notion that an appropriate c-myc silencing agent might provide a broadly appl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habib, Saffiya, Ariatti, Mario, Singh, Moganavelli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765184/ https://www.ncbi.nlm.nih.gov/pubmed/33333729 http://dx.doi.org/10.3390/biomedicines8120612

Ejemplares similares

Anti- c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro
por: Habib, Saffiya, et al.
Publicado: (2021)

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
por: Habib, Saffiya, et al.
Publicado: (2021)

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review
por: Habib, Saffiya, et al.
Publicado: (2022)

A technical note on emerging combination approach involved in the onconanotherapeutics
por: Iqubal, Mohammad Kashif, et al.
Publicado: (2022)

Biogenic Synthesis of Silver-Core Selenium-Shell Nanoparticles Using Ocimum tenuiflorum L.: Response Surface Methodology-Based Optimization and Biological Activity
por: Olawale, Femi, et al.
Publicado: (2021)

Poly-L-Lysine–Lactobionic Acid-Capped Selenium Nanoparticles for Liver-Targeted Gene Delivery
por: Naidoo, Shaigan, et al.
Publicado: (2022)

HER2/neu Oncogene Silencing in a Breast Cancer Cell Model Using Cationic Lipid-Based Delivery Systems
por: Balgobind, Adhika, et al.
Publicado: (2023)

Cytofectin Amine Head Group Modification and Degree of Liposome Pegylation: Factors Influencing Gene Transfer
por: Daniels, Aliscia, et al.
Publicado: (2011)

Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo
por: Wang, Yi-hua, et al.
Publicado: (2005)

RNAi2013: RNAi at Oxford
por: Mulcahy, Laura A, et al.
Publicado: (2013)

RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG(2) human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell
por: Zhao, Yan, et al.
Publicado: (2013)

Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics
por: Chen, Bing-Jia, et al.
Publicado: (2014)

RNAi2015 – Ten years of RNAi Oxford
por: Bewicke-Copley, Findlay, et al.
Publicado: (2015)

The knockdown of c-myc expression by RNAi inhibits cell proliferation in human colon cancer HT-29 cells in vitro and in vivo
por: Zhang, Xiao, et al.
Publicado: (2009)

RNAi-Based Functional Genomics in Hemiptera
por: Jain, Ritesh G., et al.
Publicado: (2020)

Progress on RNAi-based molecular medicines
por: Chen, Jing, et al.
Publicado: (2012)

Delivery of RNAi-Based Oligonucleotides by Electropermeabilization
por: Chabot, Sophie, et al.
Publicado: (2013)

Polymerized Selenium Nanoparticles for Folate-Receptor-Targeted Delivery of Anti-Luc-siRNA: Potential for Gene Silencing
por: Maiyo, Fiona, et al.
Publicado: (2020)

c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease
por: Zheng, Kang, et al.
Publicado: (2017)

Defense Mechanisms against Viral Infection in Drosophila: RNAi and Non-RNAi
por: Swevers, Luc, et al.
Publicado: (2018)

RNAi at Oxford
por: Aleckovic, Masa, et al.
Publicado: (2008)

Cervical cancer: a meta-analysis, therapy and future of nanomedicine
por: Venkatas, Jeaneen, et al.
Publicado: (2020)

Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy
por: Moodley, Thashini, et al.
Publicado: (2021)

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases
por: Jagaran, Keelan, et al.
Publicado: (2021)

Lipid Nanoparticles: Promising Treatment Approach for Parkinson’s Disease
por: Jagaran, Keelan, et al.
Publicado: (2022)

Protein-based vehicles for biomimetic RNAi delivery
por: Pottash, Alex Eli, et al.
Publicado: (2019)

Nano-based delivery of RNAi in cancer therapy
por: Xin, Yong, et al.
Publicado: (2017)

RNAi-Based Approaches for Pancreatic Cancer Therapy
por: Kim, Min Ju, et al.
Publicado: (2021)

RNAi-Based Antiviral Innate Immunity in Plants
por: Jin, Liying, et al.
Publicado: (2022)

Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
por: Madden, Sarah K., et al.
Publicado: (2021)

GenomeRNAi: a database for cell-based RNAi phenotypes
por: Horn, Thomas, et al.
Publicado: (2007)

C-myc and N-myc in the developing brain
por: Wey, Alice, et al.
Publicado: (2010)

Viral Vectors Applied for RNAi-Based Antiviral Therapy
por: Lundstrom, Kenneth
Publicado: (2020)

Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
por: Zhou, Jiehua, et al.
Publicado: (2013)

In Vivo RNAi-Based Screens: Studies in Model Organisms
por: Yamamoto-Hino, Miki, et al.
Publicado: (2013)

RNAi-Based Therapy: Combating Shrimp Viral Diseases
por: Alam, Md. Shahanoor, et al.
Publicado: (2023)

Target c-Myc to treat pancreatic cancer
por: Ala, Moein
Publicado: (2022)

Manipulating and enhancing the RNAi response
por: Joyce, Peter I, et al.
Publicado: (2006)

RNAi Therapeutics in Autoimmune Disease
por: Pauley, Kaleb M., et al.
Publicado: (2013)

RNAi Crop Protection Advances
por: Hernández-Soto, Alejandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ja7oih9miog2i1ev2662ljjev6